Culture

Culture · Biography

1927–1993

David Hungerford

David Hungerford supplied chromosome-analysis expertise to a collaboration that identified a recurring abnormality in a particular form of leukaemia.

United States Not independently established Updated 7 November 2026
Photo pending permission
In this biography

Quick facts

Born
1927
Died
1993
Birthplace
Not independently established
Nationality
Not independently established
Known for
Co-discovering the Philadelphia chromosome through microscopic studies of leukaemia cells

Why this life matters

His work demonstrates why the person who recognises and interprets a laboratory image is an essential research collaborator.

Timeline

Key moments

  1. Birth

    Life year recorded in a professional historical account.

  2. Doctoral degree

    Completed his doctorate at the University of Pennsylvania.

  3. Death

    Died on 3 November 1993.

Expertise behind the microscope

David Hungerford, born in 1927, was a cytogeneticist whose expertise helped connect human chromosome analysis with cancer research. A participant history records his training in chromosome cytology during the early 1950s with Jack Schultz, George Rudkin and T. S. Hauschka. That background matters because noticing an unusual feature requires more than access to a microscope. It requires familiarity with preparations, ordinary variation and the limits of the available methods, as well as the judgment to recognise an observation worth pursuing.

Sources for this section: [5] · [2]

A doctoral collaboration

At the time of the Philadelphia chromosome observation, Hungerford was a junior research fellow pursuing doctoral research through the University of Pennsylvania. Fox Chase’s history dates the initial observation to 1959 and records his doctorate in 1961. His collaboration with pathologist Peter Nowell brought together chromosome-analysis expertise and cultured clinical material. Their partnership is a clear example of work that crosses institutional and disciplinary boundaries: neither a supply of patient cells nor microscopy alone describes the whole chain that produced the finding.

Sources for this section: [1]

An observation whose interpretation changed

Nowell’s later account gives Hungerford a central role in recognising the small chromosome and improving its assignment as further material and better preparations became available. The earliest interpretation was not the complete explanation recognised today. Janet Rowley’s 1973 report subsequently used chromosome-banding evidence to suggest a rearrangement involving chromosomes 9 and 22. Keeping these contributions separate credits Hungerford’s observation without assigning him a later finding, and credits Rowley without implying that the earlier observation lacked value until its mechanism was better understood.

Sources for this section: [3] · [4]

A career remembered through collaboration

Hungerford’s research career was curtailed by illness, and he died in 1993. Fox Chase has continued to commemorate his contribution to the Philadelphia chromosome discovery. His biography illustrates an easily missed category of scientific work: preparing and reading the material through which a clinical question becomes a reproducible biological observation. Later accounts often move rapidly toward targeted medicines, but the intervening scientific steps were substantial. His own contribution remains meaningful at its original scale, as part of a collaboration that made a previously unseen pattern visible.

Sources for this section: [2] · [6] · [1]

Quick answers

Frequently asked questions about David Hungerford

What is David Hungerford known for?
Co-discovering the Philadelphia chromosome through microscopic studies of leukaemia cells.

Keep exploring

Lives connected to this story

  • Peter Nowell

    Compare the recurring marker with a later model of clonal evolution.

  • Janet Rowley

    Read the scientist who used banding methods to investigate the rearrangement.

  • Brian Druker

    Follow a later, distinct stage of molecularly directed research.

Sources and further reading

Explore the evidence

These references support the biography and offer further reading. Official records, first-person accounts and independent reporting provide different perspectives; image records document attribution and licensing.

  1. 1. Fox Chase Cancer CenterThe Philadelphia Chromosome: History and Implications for the Future

    Institutional account of1959 observation, Hungerford’s junior research fellowship and doctoral status,1961 doctorate and collaboration with Nowell. Modern mechanism is not inserted into the initial observation.

  2. 2. Cancer Research / PMCPhiladelphia Chromosome Symposium: commemoration of the50th anniversary

    Participant symposium history: Hungerford’s1951–55 cytology training with Schultz, Rudkin and Hauschka, complementary collaboration and later technical advances. Its attribution of death to multiple sclerosis conflicts with contemporary reports; cause of death is omitted.

  3. 3. Current Contents / University of Pennsylvania archiveA minute chromosome — Citation Classic commentary

    Nowell’s complete one-page1984 recollection, especially early altered-Y hypothesis and later reassignment as improved preparations and additional cases became available. Shared200-word allowance with Nowell pages.

  4. 4. NatureA New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia

    Complete1973 publisher abstract: nine patients, quinacrine/Giemsa observations, extra material on chromosome9 and suggestion of a9/22 translocation. No full-paper tables or images reviewed.

  5. 5. GeneticsBloom’s syndrome: a Mendelian prototype of somatic mutational disease

    James German’s participant historical note recording Hungerford’s life years1927–1993; no unrelated Bloom syndrome claims used.

  6. 6. Fox Chase Cancer Center / Cancer History ProjectDavid Hungerford and the Philadelphia Chromosome

    Fox Chase article dated11May2021, specifically institutional recognition and death on3November1993. Promotional claims that all targeted therapies spare normal cells are not adopted.

Back to top ↑